首页 | 本学科首页   官方微博 | 高级检索  
     

益心舒胶囊联合替格瑞洛治疗急性心肌梗死的临床研究
引用本文:刘永民,焦学昌,周国锋,何小雪,李艳君,王强,贾振,周仙草. 益心舒胶囊联合替格瑞洛治疗急性心肌梗死的临床研究[J]. 现代药物与临床, 2022, 37(2): 305-309. DOI: 10.7501/j.issn.1674-5515.2022.02.013
作者姓名:刘永民  焦学昌  周国锋  何小雪  李艳君  王强  贾振  周仙草
作者单位:安阳市第三人民医院 心内六科,河南 安阳 455000
基金项目:河南省医学科技攻关计划(联合共建)项目(LHGJ20191277)
摘    要:目的探讨益心舒胶囊联合替格瑞洛片治疗急性心肌梗死的临床疗效。方法选取2020年4月—2021年8月安阳市第三人民医院收治的88例急性心肌梗死患者,根据随机数字表法将所有患者分为对照组和治疗组,各包括44例。对照组患者口服替格瑞洛片,90mg/次,2次/d。治疗组患者在对照组基础上口服益心舒胶囊,1.2g/次,3次/d。两组在治疗1个月后统计疗效。观察两组临床疗效,比较两组治疗前后心功能指标、血小板聚集率、血栓指标。结果治疗后,治疗组患者的总有效率(88.64%)比对照组(70.45%)高(P<0.05)。治疗后,两组的左心室射血分数(LVEF)、每搏输出量(SV)明显升高,二尖瓣舒张早期血流峰速度与二尖瓣环舒张早期运动峰速度之比(E/Em)显著降低(P<0.05);且治疗后治疗组的LVEF、SV高于对照组,E/Em低于对照组(P<0.05)。治疗后,两组的血小板聚集率显著降低(P<0.05),且治疗组血小板聚集率较对照组降低更明显(P<0.05)。治疗后,两组的血浆凝血酶抗凝血酶复合物(TAT)、血栓调节蛋白(TM)、纤溶酶-α2纤溶酶抑制物复合物(PIC...

关 键 词:益心舒胶囊  替格瑞洛片  急性心肌梗死  心功能  血小板聚集率  血栓指标
收稿时间:2021-11-04

Clinical study on Yixinshu Capsules combined with ticagrelor in treatment of acute myocardial infarction
LIU Yong-min,JIAO Xue-chang,ZHOU Guo-feng,HE Xiao-xue,LI Yan-jun,WANG Qiang,JIA Zhen,ZHOU Xian-cao. Clinical study on Yixinshu Capsules combined with ticagrelor in treatment of acute myocardial infarction[J]. Drugs & Clinic, 2022, 37(2): 305-309. DOI: 10.7501/j.issn.1674-5515.2022.02.013
Authors:LIU Yong-min  JIAO Xue-chang  ZHOU Guo-feng  HE Xiao-xue  LI Yan-jun  WANG Qiang  JIA Zhen  ZHOU Xian-cao
Affiliation:Six Departments of Cardiology, Anyang Third People''s Hospital, Anyang 455000, China
Abstract:Objective To investigate the clinical efficacy of Yixinshu Capsules combined with Ticagrelor Tablets in treatment of acute myocardial infarction. Methods Patients (90 cases) with acute myocardial infarction in Anyang Third People''s Hospital from April 2020 to August 2021 were randomly divided into control and treatment groups, and each group had 44 cases. Patients in the control group were po administered with Ticagrelor Tablets, 90 mg/time, twice daily. Patients in the treatment group were po administered with Yixinshu Capsules on the basis of the control group, 1.2 g/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacies were evaluated, and cardiac function index, platelet aggregation rate, and thrombus index in two groups were compared. Results After treatment, the total effective rate of the treatment group (88.64%) was higher than that of the control group (70.45%) (P < 0.05). After treatment, the LVEF and SV in two groups were significantly increased, but the E/Em in two groups were significantly decreased (P < 0.05). After treatment, the LVEF and SV in the treatment group were higher than those in the control group, but the E/Em in the treatment group was lower than those in the control group (P < 0.05). After treatment, the platelet aggregation rate of two groups were significantly decreased (P < 0.05), and the platelet aggregation rate of the treatment group was significantly lower than that of the control group (P < 0.05). After treatment, the TAT, TM, and PIC of two groups were significantly decreased (P < 0.05), and the TAT, TM, and PIC of the treatment group were significantly lower than those of the control group (P< 0.05). Conclusion Yixinshu Capsules combined with Ticagrelor Tablets is effective in treatment of acute myocardial infarction, which can improve cardiac function, reduce platelet aggregation rate, and regulate platelet secretion, with good drug safety.
Keywords:Yixinshu Capsules  Ticagrelor Tablets  acute myocardial infarction  cardiac function  platelet aggregation rate  thrombus index
本文献已被 万方数据 等数据库收录!
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号